Celavie Biosciences to Present at April 2020 Virtual Investor Summit

Celavie Biosciences, LLC, a company working to improve lives and restore hope by advancing innovations in CNS diseases with regenerative stem cell-based therapies, today announced that the Company will give a corporate presentation at the April 2020 Virtual Investor Summit, taking place online from April 22-23, 2020. Sandy Solmon, the Company's President and Chief Executive Officer, will also give a corporate overview and update on recent momentum at Celavet Inc., a subsidiary of Celavie Biosciences that develops stem cell-based therapies for the treatment and prevention of orthopedic injuries and diseases in large and small animals. The presentation will take place on Thursday, April 23, 2020 at 1:00pm ET, followed by a live Q&A session with registered investors and other conference attendees.

A live webcast of the presentation will be available here. Following the conference, an archived version of the webcast will be available under the News section of the Company's website.

Presentation Details
Date: Thursday, April 23, 2020
Time: 1:00pm ET
Webcast link: https://bit.ly/2K6GXBH

About the Virtual Investor Summit
The April 2020 Virtual Investor Summit will take place on April 22^nd and 23^rd from 10:00am ? 3:00pm ET on both days. The event will feature presentations from public and private companies in multiple industries including life sciences/biotech, infrastructure and transportation. As part of the event, management teams will present a live audio webcast accompanied by a slide presentation and be available to participate in virtual Q&A sessions immediately following their presentation. Investors, media and interested parties can access the event schedule and individual company webcast details at the event website, virtualinvestorsummit.com.

About Celavie Biosciences
Celavie Biosciences is a?privately-held?company whose mission is to improve lives and restore hope by advancing regenerative stem cell therapies for the treatment of Parkinson's disease and other disorders of the central nervous system (CNS). The company develops undifferentiated, unmodified allogeneic pluripotent stem cell-based?therapies, holds a strong IP portfolio, including 18 issued patents,?and has an experienced management team blending expertise in concept and cell technology, product scalability?and entrepreneurship.?Celavet, a subsidiary, applies the same proprietary technologies for the treatment and prevention of serious veterinary diseases. More information is available at?https://www.celavie.com/.??